 1
Quantum Pharma Plc Annual Report and Accounts 2015
2013 2014 2015
61.7
53.5
48.3
2013 2014 2015
9.0
49.7
44.6
2013 2014 2015
12.2
9.1 9.2
2013 2014 2015
9.7
6.8
3.6
• Revenue increased by 15% to £61.7 million (2014: £53.5 million)
• Operating profit up by 191% to £6.7 million (2014: £2.3 million)
• Adjusted EBITDA increased by 34% to £12.2 million (2014: £9.1 million)
1,2
• Underlying pre-tax profit up by 73% to £5.7 million (2014: £3.3 million)
2
• Adjusted EPS of 9.7 pence (2014: 6.8 pence)
3,4
• Research and development expenditure more than doubled to £3.1 million
(2014: £1.5 million)
• Net debt reduced by 82% to £9 million (2014: £49.7 million)
5
• Proposed final dividend of 0.25 pence per share
• Successful admission to AIM on 11 December 2014, raising £106.1 million
• Significant de-gearing of the balance sheet
• Colonis’ first product, Aviticol
™
 20 000 IU Capsules, successfully launched
• Colonis’ second product licensed and being manufactured ready for launch
• 10 other products (SKUs) in assessment with the Medicines and Healthcare
products Regulatory Agency (MHRA)
• Colonis pipeline almost doubled from 31 to around 60 products
• Three year exclusive contract to supply Well Pharmacy (formerly Co-op
Pharmacy) with all unlicensed medicines and special obtains to their
774 pharmacies
Post year end: 
• Acquisition of the Lamda group of companies for €9.7 million
6
, providing
an increased product pipeline, in-house development capability and 
access to new markets 
1. EBITDA – Earnings before interest, tax, depreciation and amortisation.
2. Adjusted EBITDA and underlying pre-tax profit exclude share based payments of £2.1 million, a one-off loan 
release of £1.6 million and non-underlying costs of £4.2 million.
3. EPS – Earnings per share.
4. Adjusted EPS is based on profit after tax and adjusted to exclude share based payments of £2.1 million, 
a one-off loan release of £1.6 million, non-underlying costs of £4.2 million, one-off debt issue costs of 
£1.3 million and the tax impact of these adjustments of £1.2 million.
5. Net debt is Group loans and borrowings less cash and cash equivalents.
6. €4.7 million payable in cash on completion and two deferred amounts of €2.5 million payable in cash in 
each of April 2016 and April 2017.
Highlights
REVENUE (£M)
 61.7m
+15.0%
ADJUSTED EPS (P)
 9.7p
+43.0%
ADJUSTED EBITDA (£M)
 12.2m
+34.0%
NET DEBT (£M)
 9.0m
-82.0%
Strategic Report 
1-21
Highlights 1
About Us 2
Chairman’s Statement 6 
CEO’s Review 8
Financial Review 14
KPIs 18
Principal Risks and Uncertainties 19
Being a Responsible Business 20
Directors’ Report 
22-28
Board of Directors 22
Senior Management 23
Corporate Governance Statement 24
Directors’ Report 26
Financial Statements 
29-68
Independent Auditor’s Report 29
Consolidated Income Statement 30 
Consolidated Statement of 
Comprehensive Income 31
Consolidated Balance Sheet 32
Consolidated Statements of 
Changes in Equity 33
Consolidated Cash Flow Statements 35
Notes 36
Company Balance Sheet 63 
Reconciliations of Movements 
in Shareholders’ Funds 64
Notes 65
Contents
Strategic Report Directors’ Report Financial Statements
